Results 81 to 90 of about 74,509 (297)
The genomics of neonatal abstinence syndrome [PDF]
, 2017 Significant variability has been observed in the development and severity of neonatal abstinence syndrome (NAS) among neonates exposed to prenatal opioids.
Cole, F. Sessions +2 more
core +3 more sources
Clinical Pharmacology &Therapeutics, EarlyView.Overview of a multi‐omics based drug repurposing strategy. The systematic drug repurposing strategy included the following steps: (1) osteoporosis driver signaling networks were identified from multi‐omics data; (2) drug functional modules were obtained using a network fusion approach to integrate drug similarity information; (3) all drugs were ranked ...
Dan‐Yang Liu +21 more
wiley +1 more source
Journal of Pharmaceutical Policy and PracticeBackground Pharmacogenomics, a key component of precision medicine, aims to improve healthcare outcomes. As pharmacists play a pivotal role in this evolving field, an assessment of their preparedness to apply pharmacogenomics is imperative.Methods In ...
Mohanad Odeh +4 more
doaj +1 more source
Seminars in Perinatology, 2020 Pregnant women frequently take prescription and over the counter medications. The efficacy of medications is affected by the many physiological changes during pregnancy, and these events may be further impacted by genetic factors. Research on pharmacogenomic and pharmacokinetic influences on drug disposition during pregnancy has lagged behind other ...
Hannah K. Betcher +2 more
openaire +4 more sources
Clinical Pharmacology &Therapeutics, EarlyView.Germline pharmacogenetics (PGx) is increasingly used to tailor medication selection/dosing. However, existing systems primarily communicate PGx results to providers, limiting direct patient engagement. To address this, we developed YourPGx Oncology, an innovative patient‐facing portal that delivers multi‐gene PGx results (CYP2D6, UGT1A1, DPYD) through ...
Youngwoo Cho +15 more
wiley +1 more source
Pharmacogenetic Implementation Studies—Lessons Learned From the PREPARE Study
Clinical Pharmacology &Therapeutics, EarlyView.The Ubiquitous Pharmacogenomics consortium (www.upgx.eu) has recently completed and published the Preemptive Pharmacogenomic Testing for Preventing Adverse Drug Reactions (PREPARE) study on the implementation of panel‐based pharmacogenetic testing. PREPARE has provided interesting lessons for the design, execution, and interpretation of future clinical
Henk‐Jan Guchelaar +37 more
wiley +1 more source
Correction to the pathogenic alternative splicing, caused by the common GNB3 c.825C>T allele, using a novel, antisense morpholino [PDF]
, 2016 The very common GNB3 c.825C>T polymorphism (rs5443), is present in approximately half of all human chromosomes. Significantly the presence of the GNB3 825T allele has been strongly associated, with predisposition to essential hypertension ...
Lester, Douglas H. +2 more
core +3 more sources
Clinical Pharmacology &Therapeutics, EarlyView.This study assessed the use of 35 pharmacogenomic (PGx) medications listed in the Royal College of Pathologists of Australasia (RCPA) guideline, estimated the potential costs of subsidizing PGx testing in Australia, and predicted related prescribing changes.
Bella D. Ianni +3 more
wiley +1 more source
How Can We Move Clinical Genomics Beyond the Hype? [PDF]
, 2011 Examines the debate over increased use of genetic testing, due in part to lax regulation, and its consequences: wasteful spending, patient harm, and health system challenges.
Michael L. Millenson
core
Clinical Pharmacology &Therapeutics, EarlyView.CYP2D6 alleles with low frequency in Eurocentrically biased study populations are often excluded from pharmacogenetic investigation and consequently may have misassigned activity values. This health inequity may be contributing to imprecise dose predictions for CYP2D6‐metabolizing drugs.
Oyinlade Kehinde +6 more
wiley +1 more source